Cargando…

A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy

The indication for neoadjuvant chemotherapy (NAC) has recently broadened to include its use in the treatment of initial stage breast cancer. Axillary lymph node metastasis after NAC in breast cancer is a poor prognostic factor. Thus, the prediction of lymph node metastasis is important to estimate t...

Descripción completa

Detalles Bibliográficos
Autores principales: MOROHASHI, SATOKO, YOSHIZAWA, TADASHI, SEINO, HIROKO, HIRAI, HIDEAKI, HAGA, TOSHIHIRO, OTA, RIE, WU, YUNYAN, YOSHIDA, ERI, HAKAMADA, KENICHI, KIJIMA, HIROSHI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811402/
https://www.ncbi.nlm.nih.gov/pubmed/26935647
http://dx.doi.org/10.3892/or.2016.4635
_version_ 1782423947464146944
author MOROHASHI, SATOKO
YOSHIZAWA, TADASHI
SEINO, HIROKO
HIRAI, HIDEAKI
HAGA, TOSHIHIRO
OTA, RIE
WU, YUNYAN
YOSHIDA, ERI
HAKAMADA, KENICHI
KIJIMA, HIROSHI
author_facet MOROHASHI, SATOKO
YOSHIZAWA, TADASHI
SEINO, HIROKO
HIRAI, HIDEAKI
HAGA, TOSHIHIRO
OTA, RIE
WU, YUNYAN
YOSHIDA, ERI
HAKAMADA, KENICHI
KIJIMA, HIROSHI
author_sort MOROHASHI, SATOKO
collection PubMed
description The indication for neoadjuvant chemotherapy (NAC) has recently broadened to include its use in the treatment of initial stage breast cancer. Axillary lymph node metastasis after NAC in breast cancer is a poor prognostic factor. Thus, the prediction of lymph node metastasis is important to estimate the prognosis of breast cancer patients after NAC. Therefore, we focused on residual carcinoma patterns of primary breast tumors after NAC and examined the correlation between the patterns and lymph node metastasis. In this study, we examined 50 breast cancer specimens and associated dissected lymph nodes after NAC. We divided 40 cases into an eradicated lymph node group and a residual lymph node group to analyze residual carcinoma patterns of primary breast tumors. Residual carcinoma patterns were classified according to the cell density of carcinoma cells: dense, focal/nested and sporadic/in-situ. There were significant differences in residual carcinoma patterns (P<0.01) among the three pattern groups. There was a high incidence of dense patterns in the residual lymph node group and a high incidence of sporadic/in-situ patterns in the eradicated lymph node group. Analysis of residual carcinoma patterns of primary breast tumors and clinicopathological factors demonstrated that there were significant differences in tumor reduced ratio on CT (P<0.001), primary tumor area before NAC (P<0.01), primary tumor area after NAC (P<0.00001), intrinsic subtype (P<0.01), Ki-67 labeling index (P<0.01), histological grade (P<0.05) and mitotic count (P<0.01) between the dense and non-dense groups. Therefore, our results suggest that the residual carcinoma pattern is useful for predicting eradicated or residual lymph nodes and the malignant potential in breast cancer after NAC.
format Online
Article
Text
id pubmed-4811402
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-48114022016-04-06 A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy MOROHASHI, SATOKO YOSHIZAWA, TADASHI SEINO, HIROKO HIRAI, HIDEAKI HAGA, TOSHIHIRO OTA, RIE WU, YUNYAN YOSHIDA, ERI HAKAMADA, KENICHI KIJIMA, HIROSHI Oncol Rep Articles The indication for neoadjuvant chemotherapy (NAC) has recently broadened to include its use in the treatment of initial stage breast cancer. Axillary lymph node metastasis after NAC in breast cancer is a poor prognostic factor. Thus, the prediction of lymph node metastasis is important to estimate the prognosis of breast cancer patients after NAC. Therefore, we focused on residual carcinoma patterns of primary breast tumors after NAC and examined the correlation between the patterns and lymph node metastasis. In this study, we examined 50 breast cancer specimens and associated dissected lymph nodes after NAC. We divided 40 cases into an eradicated lymph node group and a residual lymph node group to analyze residual carcinoma patterns of primary breast tumors. Residual carcinoma patterns were classified according to the cell density of carcinoma cells: dense, focal/nested and sporadic/in-situ. There were significant differences in residual carcinoma patterns (P<0.01) among the three pattern groups. There was a high incidence of dense patterns in the residual lymph node group and a high incidence of sporadic/in-situ patterns in the eradicated lymph node group. Analysis of residual carcinoma patterns of primary breast tumors and clinicopathological factors demonstrated that there were significant differences in tumor reduced ratio on CT (P<0.001), primary tumor area before NAC (P<0.01), primary tumor area after NAC (P<0.00001), intrinsic subtype (P<0.01), Ki-67 labeling index (P<0.01), histological grade (P<0.05) and mitotic count (P<0.01) between the dense and non-dense groups. Therefore, our results suggest that the residual carcinoma pattern is useful for predicting eradicated or residual lymph nodes and the malignant potential in breast cancer after NAC. D.A. Spandidos 2016-05 2016-02-25 /pmc/articles/PMC4811402/ /pubmed/26935647 http://dx.doi.org/10.3892/or.2016.4635 Text en Copyright: © Morohashi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
MOROHASHI, SATOKO
YOSHIZAWA, TADASHI
SEINO, HIROKO
HIRAI, HIDEAKI
HAGA, TOSHIHIRO
OTA, RIE
WU, YUNYAN
YOSHIDA, ERI
HAKAMADA, KENICHI
KIJIMA, HIROSHI
A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy
title A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy
title_full A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy
title_fullStr A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy
title_full_unstemmed A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy
title_short A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy
title_sort new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811402/
https://www.ncbi.nlm.nih.gov/pubmed/26935647
http://dx.doi.org/10.3892/or.2016.4635
work_keys_str_mv AT morohashisatoko anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT yoshizawatadashi anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT seinohiroko anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT hiraihideaki anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT hagatoshihiro anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT otarie anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT wuyunyan anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT yoshidaeri anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT hakamadakenichi anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT kijimahiroshi anewhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT morohashisatoko newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT yoshizawatadashi newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT seinohiroko newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT hiraihideaki newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT hagatoshihiro newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT otarie newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT wuyunyan newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT yoshidaeri newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT hakamadakenichi newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy
AT kijimahiroshi newhistologicaltherapeuticclassificationsystemtopredicteradicatedandresiduallymphnodesinbreastcancerafterneoadjuvantchemotherapy